Market Risers: Allergy Therapeutics, AstraZeneca, Bunzl

Broker Ratings

Shares of Allergy Therapeutics with EPIC code: LON:AGY has risen 3.55% or 1.25 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The high for the period has peaked at 36.5 dipping to 35. The volume total for shares traded up to this point was 284,040 with the average number of shares traded daily being 506,977. The 52 week high is 40.5 about 5.25 points difference from the previous close and the 52 week low at 12.75 is a variance of 22.5 points. Allergy Therapeutics has a 20 SMA of 36.91 and now the 50 day SMA of 36.08. Market capitalisation is now £234.26m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Allergy Therapeutics being recorded at Tuesday, November 2, 2021 at 12:36:28 PM GMT with the stock price trading at 36.5 GBX.

Stock in AstraZeneca found using EPIC: LON:AZN has gained 1.12% or 102 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The period high has peaked at 9275 meanwhile the session low reached 9157.81. Volume total for shares traded at this point reached 308,872 whilst the daily average number of shares exchanged is just 1,901,970. The 52 week high for the shares is 9275 some 137 points different to the previous business close and a 52 week low sitting at 6736 a difference of some 2402 points. AstraZeneca now has a 20 SMA at 8962.84 and now the 50 day moving average now at 8747.35. This puts the market capitalisation now at £144,185.74m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, November 2, 2021 at 12:35:26 PM GMT with the stock price trading at 9240 GBX.

Stock in Bunzl with EPIC code: LON:BNZL has risen 1.33% or 36 points throughout today’s trading session so far. Buyers have remained optimistic throughout the session. Range high for the period so far is 2745 and a low of 2690. Volume total for shares traded at this point reached 228,634 with the daily average at 699,886. The 52 week high price for the shares is 2745 about 43 points in difference to the previous days close of business and a 52 week low sitting at 2122 making a difference of 580 points. Bunzl now has a 20 SMA at 2552.61 and now a 50 day MA at 2570.22. This puts the market capitalisation now at £9,260.41m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Bunzl being recorded at Tuesday, November 2, 2021 at 12:31:23 PM GMT with the stock price trading at 2738 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers.

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg.

Bunzl Plc reports steady Q3 trading, reaffirms 2025 outlook

Bunzl plc has reported a 0.6% increase in Q3 revenue at constant exchange rates, with underlying revenue up 0.4% despite challenging market conditions.

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps.

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients.

Bunzl Plc expands with acquisitions in Ireland and Spain

Bunzl =has completed the acquisitions of Caterline Catering Equipment Ltd in Ireland and Anta y Jesús, S.L.U in Spain, each generating revenue of €6 million (£5 million) in 2024.

Search

Search